Business Wire·Jun 8, 2026, 7:00 AM ET

Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders

Incyte has entered a definitive agreement to acquire Vega Therapeutics, a wholly owned subsidiary of Star Therapeutics, for an upfront payment of $1.25 billion.
Star Therapeutics may receive up to $750 million in additional payments upon achieving sales milestones, bringing the total potential consideration to $2.0 billion.
The acquisition will add VGA039, a novel investigational monoclonal antibody targeting Protein S, to Incyte's hematology portfolio.
VGA039 is in Phase 3 pivotal development (VIVID-6 study) for von Willebrand disease (VWD), the most common inherited bleeding disorder affecting approximately 135,000 people in the U.S.
The therapy aims to be the first subcutaneous prophylactic option for VWD, offering a once-monthly dosing regimen compared to current treatments requiring frequent intravenous infusions.
VGA039 holds FDA designations including Breakthrough Therapy, Fast Track, orphan drug, and rare pediatric disease status.
The transaction has been approved by both companies' Boards of Directors and is expected to close in the third quarter of 2026, pending Hart-Scott-Rodino review.
Incyte expects to record an R&D charge of approximately $1.25 billion related to the equity acquisition in its third quarter and full year 2026 financial results.
An analyst and investor call is scheduled for Monday, June 8, 2026, at 8:00 a.m. ET to discuss the acquisition details.